Puhr Hannah C, Reiter Thorsten J, El-Mahrouk Mohamed, Saliternig Lena, Wolf Peter, Mair Maximilian J, Steindl Ariane, Paireder Matthias, Asari Reza, Schoppmann Sebastian F, Berghoff Anna S, Preusser Matthias, Ilhan-Mutlu Aysegül
Department of Medicine I, Division of Oncology, Medical University of Vienna, 1090 Vienna, Austria.
Comprehensive Cancer Center Vienna, Medical University of Vienna, 1090 Vienna, Austria.
Cancers (Basel). 2021 Oct 9;13(20):5050. doi: 10.3390/cancers13205050.
As thyroid hormones modulate proliferative pathways it is surmised that they can be associated with cancer development. Since the potential association of gastroesophageal cancer and thyroid disorders has not been addressed so far, the aim of this study was to investigate the association of thyroid hormone parameters with the outcome of these patients, so novel prognostic and even potentially therapeutic markers can be defined.
Clinical and endocrinological parameters of patients with resectable gastroesophageal cancer treated between 1990 and 2018 at the Vienna General Hospital, Austria, including history of endocrinological disorders and laboratory analyses of thyroid hormones at first cancer diagnosis were investigated and correlated with the overall survival (OS).
In a total of 865 patients, a tendency towards prolonged OS in hypothyroid patients (euthyroid, = 647: median OS 29.7 months; hyperthyroid, = 50: 23.1 months; hypothyroid, = 70: 47.9 months; = 0.069) as well as a significant positive correlation of thyroid hormone replacement therapy with the OS was observed (without, = 53: median OS 30.6 months; with, = 67: 51.3 months; = 0.017). Furthermore, triiodothyronine (T3) levels were also associated with the OS (median OS within the limit of normal: 23.4, above: 32.4, below: 9.6 months; = 0.045).
Thyroid disorders and their therapeutic interventions might be associated with the OS in patients with resectable gastroesophageal cancer. As data on the correlation of these parameters is scarce, this study proposes an important impulse for further analyses concerning the association of thyroid hormones with the outcome in patients with gastroesophageal tumors.
由于甲状腺激素可调节增殖途径，因此推测它们可能与癌症发展有关。鉴于目前尚未探讨过食管癌与甲状腺疾病之间的潜在关联，本研究旨在调查甲状腺激素参数与这些患者预后的关系，从而确定新的预后指标甚至潜在的治疗指标。
对1990年至2018年在奥地利维也纳总医院接受治疗的可切除食管癌患者的临床和内分泌参数进行了调查，包括内分泌疾病史以及首次癌症诊断时甲状腺激素的实验室分析，并将其与总生存期（OS）进行关联分析。
在总共865例患者中，甲状腺功能减退患者有总生存期延长的趋势（甲状腺功能正常者，n = 647：中位总生存期29.7个月；甲状腺功能亢进者，n = 50：23.1个月；甲状腺功能减退者，n = 70：47.9个月；P = 0.069），并且观察到甲状腺激素替代治疗与总生存期呈显著正相关（未接受治疗者，n = 53：中位总生存期30.6个月；接受治疗者，n = 67：51.3个月；P = 0.017）。此外，三碘甲状腺原氨酸（T3）水平也与总生存期相关（正常范围内的中位总生存期：23.4个月，高于正常范围：32.4个月，低于正常范围：9.6个月；P = 0.045）。
甲状腺疾病及其治疗干预可能与可切除食管癌患者的总生存期有关。由于关于这些参数相关性的数据较少，本研究为进一步分析甲状腺激素与食管癌患者预后的关系提供了重要推动。
